Qulipta denials in California external review

What the reviewers wrote

Where the denial was overturned

Findings: The physician reviewer found that Nature of Statutory Criteria/Case Summary: The patient has requested authorization and coverage for Qulipta. Qulipta is the first oral calcitonin gene-related peptide (CGRP) antagonist that has been approved by the U.S. Food and Drug Administration (FDA) for the indication of chronic migraine prevention. One study reported that CGRP plays a crucial role in migraine pathophysiology and is now established as an important target for both preventive and acute treatments. The authors noted that the currently approved preventive CGRP-targeting treatments are monoclonal antibodies that bind either the CGRP receptor or the CGRP ligand.

Nature of Statutory Criteria/Case Summary: The patient has requested authorization and coverage for (1) Qulipta 60 mg tablet, and (2) Trudhesa aerosol solution 0.725 mg/actuation, 1 mL nasal spray (12 mL per 28 days). Scuteri and colleagues report that calcitonin-gene related peptide (CGRP) antagonists play a fundamental role in migraine pharmacotherapy. Rustichelli and colleagues describe atogepant (brand name Qulipta), an orally active small molecule, as a potent, selective antagonist of the CGRP receptor and as the only gepant authorized exclusively for episodic migraine prophylaxis in adults. Qulipta is also an option for women of childbearing age, as it has a very short half-life in comparison to other medications that block CGRP activity such as Aimovig. This allows a much faster elimination time from the body if necessary.

Where the denial was upheld

Findings: The physician reviewer found that Nature of Statutory Criteria/Case Summary: A patient has requested authorization and coverage for Qulipta. Migraines are a primary headache disorder characterized by recurrent attacks of moderate-to-severe headaches, often accompanied by nausea, vomiting, and sensitivity to light and sound. Irritable bowel syndrome is a functional gastrointestinal disorder that frequently coexists with migraine, likely due to shared pathogenic mechanisms involving the brain-gut axis and serotonergic pathways. For preventive treatment of chronic migraine, medical guidelines recommend calcitonin gene-related peptide (CGRP) antagonist monoclonal antibodies such as Ajovy and Emgality as first-line options due to their proven efficacy and favorable safety profile.

Findings: The physician reviewer found that An enrollee has requested authorization and coverage for Qulipta. Calcitonin gene-related peptide (CGRP) plays a crucial role in migraine pathophysiology and has been established as an important target for both preventive and acute treatments (Edvinsson, et al.). Per the American Headache Society (AHS), Aimovig is an injectable monoclonal antibody targeting the CGRP receptor. Ubrelvy is an oral CGRP inhibitor approved by the U.S. Food and Drug Administration (FDA) in 2019. Ubrelvy is indicated for the acute treatment of migraine with or without aura in adults. In a case report study, Mullin and colleagues concluded that concomitant use of Nurtec and Ubrelvy may involve additive effects and may be generalizable to other combinations of anti-CGRP agents with distinct molecular targets.

Put this treatment in the complete diagnosis-and-drug graph, with the migraine-only denominator disclosed separately: migraine, CGRP drug and Botox denial evidence guide.

These outcomes describe eligible cases completed through California DMHC’s Independent Medical Review program. They do not estimate the chance that an internal appeal, an external review in another jurisdiction, or your individual case will succeed. Use the record to identify evidence patterns involving Qulipta, then check the rights and deadlines that apply to your plan.